Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-21
1999-03-02
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 530324, 530326, C07K 706, C07K 1452, C07K 14435
Patent
active
058771514
ABSTRACT:
The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 or 120-146 of CAP37 or subunits thereof.
REFERENCES:
patent: 4652639 (1987-03-01), Stabinsky
patent: 5087569 (1992-02-01), Gabay et al.
patent: 5126257 (1992-06-01), Gabay et al.
patent: 5171739 (1992-12-01), Scott
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5338724 (1994-08-01), Gabay et al.
patent: 5447914 (1995-09-01), Travis et al.
patent: 5458874 (1995-10-01), Pereira et al.
patent: 5484885 (1996-01-01), Pereira et al.
patent: 5607916 (1997-03-01), Pereira et al.
patent: 5627262 (1997-05-01), Pereira
patent: 5650392 (1997-07-01), Pereira et al.
patent: 5652332 (1997-07-01), Little, II
patent: 5688767 (1997-11-01), Hancock et al.
Ziegler et al., "Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum To A Mutant Escherichia Coli", The New England Journal of Medicine, vol. 307, No. 20, Nov. 11, 1982.
Brackett et al., "Evaluation of Cardiac Output, Total Peripheral Vascular Resistance, and Plasma Concentrations of Vasopressin in the Conscious, Unrestrained Rat During Endotoxemia", Circulatory Shock, 17:273-284, 1985.
Baumgartner et al., "Prevention of Gram-Negative Shock and Death In Surgical Patients By Antibody to Endotoxin Core Glycolipid", The Lancet, Jul. 13, 1985, pp. 59-63.
Fisher et al., "Initial Evaluation of Human Monoclonal Anti-Lipid A Antibody (HA-1A) in Patients with Sepsis Syndrome", Critical Care Medicine, vol. 18, No. 12, 1990, 1311-1315.
Ziegler et al., "Treatment of Gram-Negative Bacteremia and Septic Shock With HA-1A Human Monoclonal Antibody against Endotoxin", The New England Jounal of Medicine, vol. 324, No. 7, Feb. 14, 1991, pp. 429-436.
Greenman et al., "A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis", JAMA, vol. 266, No. 8, Aug. 28, 1991, pp. 1097-1102 and 1125-1126.
J. Johnston, "Molecular Science Sets Its Sights on Septic Shock", The Journal of NIH Research, vol. 3, Oct. 1991, pp. 61-65.
"Anti-Endotoxin Monoclonal Antibodies", various editorials, The New England Journal of Medicine, vol. 327, No. 12, Sep. 17, 1992, pp. 889-890.
C. Welbourn and Y. Young, "Endotoxin, Septic Shock and Acute Lung Injury: Neutrophils, Macrophages and Inflammatory Mediators", Br. J. Surg., vol. 79, Oct. 1992, pp. 998-1003.
Dialog(R) file 155 Accussion No. 93226936, Offenstadt, G. et al., Jan. 1, 1993. "Therapeutic Perspectives of Severe Infectious States", REV PRAT (France), vol. 43, No. 1, Abstract only.
W. Hoffman, and C. Natanson, "Endotoxin in Septic Shock", Anesth Analg, 1993 :77 :613-24.
W. Ammons and A. Kung, "Recombinant Amino Terminal Fragment of Bactericidal/Permeability-Increasing Protein Prevents Hemodynamic Responses to Endotoxin", Circulatory Shock, 41: 176-184, 1993.
Pereira et al., "Synthetic Bactericidal Peptide Bases on CAP37: A 37kDa Human Neutrophil Granule-Associated Cationic Antimicrobial Protein Chemotactic for Monocytes", Proc. Natl. Acad. Sci. USA, vol. 90, pp. 4733-4737, May 1993.
Cross et al., Jul. 1993, "Choice of Bacteria in Animal Models of Sepsis", Infection and Immunity, vol. 61, No. 7, pp. 2741-2747.
S. Aldridge, "Meeting the Challenge of Sepsis", TIBTECH, vol. 11, Sep. 1993.
Dialog (R), File 72, Embase No. 94208915, Rogy et al., 1994. Anti-endotoxin Therapy in Primate Bacteremia With HA-1A and BPI, ANN SURG (USA), vol. 220, No. 1, Abstract only.
Stewart et al., "Comparison of Staphylococcus aureus and Escherichia coli Infusion in Conscious Rats", Journal of Surgical Research, 56, 60-66, 1994.
J. Gabay, "Ubiquitous Natural Antibiotics" Science, vol., 264, 15 Apr. 1994, pp. 373-374.
Dialog (R), File 72, Embase No. 95085016, Hurley, J.C., 1995. "Endotoxaemia and Novel Therapies for the Treatment of Sepsis", Expert Opinion on Investigational Drugs (United Kingdom), vol. 4, No. 3, Abstract only.
Moore William W.
The Board of Regents of the University of Oklahoma
Wax Robert A.
LandOfFree
Method for inhibiting production of tumor necrosis factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting production of tumor necrosis factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting production of tumor necrosis factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-422926